{"preliminary_commentary":{"by_channel":{"x_thread":15,"youtube":13,"podcast":13},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04793958\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"KRYSTAL-10","nct_id":"NCT04793958","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=krystal-10-nct04793958. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"MRTX849 + Cetuximab","type":"EXPERIMENTAL"},{"description":null,"label":"mFOLFOX6 or FOLFIRI","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-23","type":"ESTIMATED"},"conditions":["Advanced Colorectal Cancer","Metastatic Colorectal Cancer"],"enrollment":{"count":461,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"MRTX849","otherNames":[],"type":"DRUG"},{"name":"Cetuximab","otherNames":["Erbitux"],"type":"BIOLOGICAL"},{"name":"mFOLFOX6 Regimen","otherNames":[],"type":"DRUG"},{"name":"FOLFIRI Regimen","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"30 months"},{"measure":"Progression-free Survival (PFS)","timeFrame":"30 months"}],"references":[{"citation":"Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Jan 3;23(1):e247067. doi: 10.6004/jnccn.2024.7067.","pmid":"39752885","type":"DERIVED"}],"start_date":{"date":"2021-06-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","url":"https://clinicaltrials.gov/study/NCT04793958"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/krystal-10-nct04793958"}